Intrinsic value of Neos Therapeutics - NEOS

Previous Close

$6.70

  Intrinsic Value

$0.00

stock screener

  Rating & Target

str. sell

-100%

  Value-price divergence*

0%

Previous close

$6.70

 
Intrinsic value

$0.00

 
Up/down potential

-100%

 
Rating

str. sell

 
Value-price divergence*

0%

*Intrinsic value change (in %) minus stock price change (in %) in the past 12 months.

We calculate the intrinsic value of NEOS stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2016), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.1

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  125.00
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  9
  14
  22
  33
  48
  68
  94
  126
  165
  212
  268
  333
  407
  491
  584
  687
  799
  920
  1,051
  1,190
  1,338
  1,494
  1,659
  1,831
  2,012
  2,201
  2,398
  2,603
  2,817
  3,038
  3,269
Variable operating expenses, $m
 
  109
  168
  251
  365
  515
  708
  950
  1,247
  1,605
  2,027
  2,517
  3,077
  3,709
  4,413
  5,189
  6,036
  6,952
  7,938
  8,990
  10,107
  11,289
  12,532
  13,838
  15,204
  16,631
  18,120
  19,669
  21,282
  22,959
  24,701
Fixed operating expenses, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  87
  109
  168
  251
  365
  515
  708
  950
  1,247
  1,605
  2,027
  2,517
  3,077
  3,709
  4,413
  5,189
  6,036
  6,952
  7,938
  8,990
  10,107
  11,289
  12,532
  13,838
  15,204
  16,631
  18,120
  19,669
  21,282
  22,959
  24,701
Operating income, $m
  -78
  -94
  -146
  -218
  -316
  -447
  -614
  -824
  -1,082
  -1,392
  -1,758
  -2,184
  -2,670
  -3,218
  -3,829
  -4,502
  -5,237
  -6,032
  -6,887
  -7,800
  -8,770
  -9,795
  -10,874
  -12,006
  -13,192
  -14,430
  -15,722
  -17,066
  -18,465
  -19,920
  -21,432
EBITDA, $m
  -74
  -90
  -140
  -209
  -303
  -428
  -588
  -790
  -1,037
  -1,334
  -1,685
  -2,093
  -2,559
  -3,084
  -3,670
  -4,315
  -5,019
  -5,782
  -6,601
  -7,476
  -8,406
  -9,388
  -10,422
  -11,508
  -12,644
  -13,831
  -15,069
  -16,358
  -17,699
  -19,093
  -20,542
Interest expense (income), $m
  3
  4
  6
  10
  15
  22
  32
  44
  60
  79
  102
  129
  161
  197
  237
  283
  333
  387
  446
  509
  577
  649
  725
  805
  889
  977
  1,068
  1,164
  1,264
  1,367
  1,475
Earnings before tax, $m
  -83
  -98
  -152
  -228
  -332
  -469
  -646
  -868
  -1,142
  -1,471
  -1,861
  -2,313
  -2,830
  -3,415
  -4,066
  -4,784
  -5,569
  -6,419
  -7,333
  -8,309
  -9,347
  -10,443
  -11,598
  -12,811
  -14,081
  -15,407
  -16,790
  -18,230
  -19,729
  -21,288
  -22,907
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -83
  -98
  -152
  -228
  -332
  -469
  -646
  -868
  -1,142
  -1,471
  -1,861
  -2,313
  -2,830
  -3,415
  -4,066
  -4,784
  -5,569
  -6,419
  -7,333
  -8,309
  -9,347
  -10,443
  -11,598
  -12,811
  -14,081
  -15,407
  -16,790
  -18,230
  -19,729
  -21,288
  -22,907

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  40
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  80
  127
  197
  294
  427
  603
  829
  1,112
  1,460
  1,879
  2,374
  2,948
  3,604
  4,344
  5,168
  6,077
  7,069
  8,143
  9,297
  10,529
  11,838
  13,221
  14,678
  16,207
  17,807
  19,479
  21,222
  23,037
  24,925
  26,889
  28,930
Adjusted assets (=assets-cash), $m
  40
  127
  197
  294
  427
  603
  829
  1,112
  1,460
  1,879
  2,374
  2,948
  3,604
  4,344
  5,168
  6,077
  7,069
  8,143
  9,297
  10,529
  11,838
  13,221
  14,678
  16,207
  17,807
  19,479
  21,222
  23,037
  24,925
  26,889
  28,930
Revenue / Adjusted assets
  0.225
  0.110
  0.112
  0.112
  0.112
  0.113
  0.113
  0.113
  0.113
  0.113
  0.113
  0.113
  0.113
  0.113
  0.113
  0.113
  0.113
  0.113
  0.113
  0.113
  0.113
  0.113
  0.113
  0.113
  0.113
  0.113
  0.113
  0.113
  0.113
  0.113
  0.113
Average production assets, $m
  25
  39
  61
  91
  131
  185
  255
  342
  449
  578
  730
  907
  1,108
  1,336
  1,590
  1,869
  2,174
  2,505
  2,860
  3,239
  3,641
  4,067
  4,515
  4,985
  5,477
  5,991
  6,527
  7,086
  7,667
  8,271
  8,899
Working capital, $m
  33
  -1
  -2
  -3
  -5
  -7
  -9
  -13
  -17
  -21
  -27
  -33
  -41
  -49
  -58
  -69
  -80
  -92
  -105
  -119
  -134
  -149
  -166
  -183
  -201
  -220
  -240
  -260
  -282
  -304
  -327
Total debt, $m
  64
  97
  159
  247
  366
  524
  728
  983
  1,296
  1,673
  2,118
  2,635
  3,225
  3,891
  4,633
  5,451
  6,344
  7,310
  8,349
  9,458
  10,636
  11,881
  13,192
  14,568
  16,008
  17,513
  19,081
  20,715
  22,415
  24,182
  26,019
Total liabilities, $m
  82
  115
  177
  265
  384
  542
  746
  1,001
  1,314
  1,691
  2,136
  2,653
  3,243
  3,909
  4,651
  5,469
  6,362
  7,328
  8,367
  9,476
  10,654
  11,899
  13,210
  14,586
  16,026
  17,531
  19,099
  20,733
  22,433
  24,200
  26,037
Total equity, $m
  -2
  13
  20
  29
  43
  60
  83
  111
  146
  188
  237
  295
  360
  434
  517
  608
  707
  814
  930
  1,053
  1,184
  1,322
  1,468
  1,621
  1,781
  1,948
  2,122
  2,304
  2,493
  2,689
  2,893
Total liabilities and equity, $m
  80
  128
  197
  294
  427
  602
  829
  1,112
  1,460
  1,879
  2,373
  2,948
  3,603
  4,343
  5,168
  6,077
  7,069
  8,142
  9,297
  10,529
  11,838
  13,221
  14,678
  16,207
  17,807
  19,479
  21,221
  23,037
  24,926
  26,889
  28,930
Debt-to-equity ratio
  -32.000
  7.590
  8.090
  8.390
  8.580
  8.700
  8.780
  8.840
  8.880
  8.900
  8.920
  8.940
  8.950
  8.960
  8.970
  8.970
  8.970
  8.980
  8.980
  8.980
  8.980
  8.990
  8.990
  8.990
  8.990
  8.990
  8.990
  8.990
  8.990
  8.990
  8.990
Adjusted equity ratio
  -1.050
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -83
  -98
  -152
  -228
  -332
  -469
  -646
  -868
  -1,142
  -1,471
  -1,861
  -2,313
  -2,830
  -3,415
  -4,066
  -4,784
  -5,569
  -6,419
  -7,333
  -8,309
  -9,347
  -10,443
  -11,598
  -12,811
  -14,081
  -15,407
  -16,790
  -18,230
  -19,729
  -21,288
  -22,907
Depreciation, amort., depletion, $m
  4
  4
  6
  9
  13
  19
  25
  34
  45
  58
  73
  91
  111
  134
  159
  187
  217
  250
  286
  324
  364
  407
  451
  498
  548
  599
  653
  709
  767
  827
  890
Funds from operations, $m
  -70
  -94
  -146
  -219
  -318
  -450
  -620
  -834
  -1,097
  -1,414
  -1,788
  -2,222
  -2,720
  -3,281
  -3,907
  -4,598
  -5,352
  -6,169
  -7,047
  -7,986
  -8,982
  -10,037
  -11,147
  -12,313
  -13,533
  -14,808
  -16,137
  -17,522
  -18,962
  -20,460
  -22,018
Change in working capital, $m
  1
  -1
  -1
  -1
  -2
  -2
  -3
  -3
  -4
  -5
  -6
  -6
  -7
  -8
  -9
  -10
  -11
  -12
  -13
  -14
  -15
  -16
  -16
  -17
  -18
  -19
  -20
  -21
  -21
  -22
  -23
Cash from operations, $m
  -71
  -94
  -145
  -218
  -317
  -448
  -618
  -831
  -1,093
  -1,409
  -1,782
  -2,216
  -2,712
  -3,273
  -3,898
  -4,587
  -5,341
  -6,157
  -7,034
  -7,972
  -8,968
  -10,021
  -11,131
  -12,295
  -13,515
  -14,789
  -16,117
  -17,501
  -18,941
  -20,438
  -21,994
Maintenance CAPEX, $m
  0
  -2
  -4
  -6
  -9
  -13
  -19
  -25
  -34
  -45
  -58
  -73
  -91
  -111
  -134
  -159
  -187
  -217
  -250
  -286
  -324
  -364
  -407
  -451
  -498
  -548
  -599
  -653
  -709
  -767
  -827
New CAPEX, $m
  -4
  -15
  -21
  -30
  -41
  -54
  -69
  -87
  -107
  -129
  -152
  -177
  -202
  -228
  -254
  -279
  -305
  -330
  -355
  -379
  -403
  -426
  -448
  -470
  -492
  -514
  -536
  -558
  -581
  -604
  -628
Cash from investing activities, $m
  -19
  -17
  -25
  -36
  -50
  -67
  -88
  -112
  -141
  -174
  -210
  -250
  -293
  -339
  -388
  -438
  -492
  -547
  -605
  -665
  -727
  -790
  -855
  -921
  -990
  -1,062
  -1,135
  -1,211
  -1,290
  -1,371
  -1,455
Free cash flow, $m
  -90
  -111
  -170
  -254
  -367
  -515
  -706
  -944
  -1,234
  -1,583
  -1,992
  -2,465
  -3,005
  -3,611
  -4,285
  -5,026
  -5,833
  -6,704
  -7,640
  -8,637
  -9,694
  -10,811
  -11,985
  -13,217
  -14,505
  -15,851
  -17,253
  -18,712
  -20,231
  -21,809
  -23,449
Issuance/(repayment) of debt, $m
  23
  33
  63
  88
  120
  158
  203
  255
  313
  377
  445
  517
  591
  666
  742
  818
  893
  966
  1,039
  1,109
  1,178
  1,245
  1,311
  1,376
  1,440
  1,504
  1,569
  1,634
  1,700
  1,767
  1,837
Issuance/(repurchase) of shares, $m
  0
  113
  159
  238
  345
  486
  668
  897
  1,177
  1,513
  1,910
  2,370
  2,896
  3,489
  4,149
  4,875
  5,668
  6,527
  7,449
  8,433
  9,477
  10,582
  11,744
  12,964
  14,241
  15,574
  16,964
  18,412
  19,918
  21,484
  23,111
Cash from financing (excl. dividends), $m  
  24
  146
  222
  326
  465
  644
  871
  1,152
  1,490
  1,890
  2,355
  2,887
  3,487
  4,155
  4,891
  5,693
  6,561
  7,493
  8,488
  9,542
  10,655
  11,827
  13,055
  14,340
  15,681
  17,078
  18,533
  20,046
  21,618
  23,251
  24,948
Total cash flow (excl. dividends), $m
  -66
  35
  51
  72
  98
  129
  166
  208
  256
  308
  363
  422
  482
  543
  606
  667
  729
  789
  848
  905
  961
  1,016
  1,070
  1,123
  1,175
  1,228
  1,280
  1,333
  1,387
  1,442
  1,499
Retained Cash Flow (-), $m
  80
  -113
  -159
  -238
  -345
  -486
  -668
  -897
  -1,177
  -1,513
  -1,910
  -2,370
  -2,896
  -3,489
  -4,149
  -4,875
  -5,668
  -6,527
  -7,449
  -8,433
  -9,477
  -10,582
  -11,744
  -12,964
  -14,241
  -15,574
  -16,964
  -18,412
  -19,918
  -21,484
  -23,111
Prev. year cash balance distribution, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  -78
  -108
  -166
  -247
  -358
  -503
  -688
  -921
  -1,206
  -1,547
  -1,949
  -2,414
  -2,945
  -3,543
  -4,208
  -4,940
  -5,738
  -6,601
  -7,528
  -8,516
  -9,566
  -10,674
  -11,841
  -13,065
  -14,346
  -15,684
  -17,079
  -18,531
  -20,042
  -21,612
Discount rate, %
 
  8.70
  9.14
  9.59
  10.07
  10.57
  11.10
  11.66
  12.24
  12.85
  13.50
  14.17
  14.88
  15.62
  16.41
  17.23
  18.09
  18.99
  19.94
  20.94
  21.98
  23.08
  24.24
  25.45
  26.72
  28.06
  29.46
  30.93
  32.48
  34.11
  35.81
PV of cash for distribution, $m
 
  -72
  -90
  -126
  -168
  -216
  -267
  -318
  -366
  -406
  -436
  -454
  -457
  -446
  -422
  -388
  -346
  -299
  -250
  -203
  -160
  -122
  -90
  -64
  -44
  -30
  -19
  -12
  -7
  -4
  -2
Current shareholders' claim on cash, %
  100
  50.0
  3.7
  0.3
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

Neos Therapeutics, Inc., a pharmaceutical company, engages in the development, manufacture, and commercialization of products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technologies. Its product candidates are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. The company manufactures and markets generic Tussionex, a hydrocodone polistirex and chlorpheniramine polistirex XR liquid suspension product indicated for the relief of cough and upper respiratory symptoms associated with allergies or colds in adults and children of six years of age and older. Its product candidates include Adzenys XR-ODT amphetamine for the treatment of ADHD; Cotempla XR-ODT methylphenidate for the treatment of ADHD; and NT-0201 amphetamine XR liquid suspension for the treatment of ADHD. The company is headquartered in Grand Prairie, Texas.

FINANCIAL RATIOS  of  Neos Therapeutics (NEOS)

Valuation Ratios
P/E Ratio -1.3
Price to Sales 12
Price to Book -53.8
Price to Tangible Book
Price to Cash Flow -1.5
Price to Free Cash Flow -1.4
Growth Rates
Sales Growth Rate 125%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 300%
Cap. Spend. - 3 Yr. Gr. Rate 14.9%
Financial Strength
Quick Ratio 8
Current Ratio 0.2
LT Debt to Equity -2950%
Total Debt to Equity -3200%
Interest Coverage -27
Management Effectiveness
Return On Assets -78.8%
Ret/ On Assets - 3 Yr. Avg. -51.9%
Return On Total Capital -95.4%
Ret/ On T. Cap. - 3 Yr. Avg. -65.2%
Return On Equity -218.4%
Return On Equity - 3 Yr. Avg. -147.9%
Asset Turnover 0.1
Profitability Ratios
Gross Margin -22.2%
Gross Margin - 3 Yr. Avg. -124.1%
EBITDA Margin -844.4%
EBITDA Margin - 3 Yr. Avg. -1014.8%
Operating Margin -866.7%
Oper. Margin - 3 Yr. Avg. -1105.6%
Pre-Tax Margin -922.2%
Pre-Tax Margin - 3 Yr. Avg. -1265.7%
Net Profit Margin -922.2%
Net Profit Margin - 3 Yr. Avg. -1265.7%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

NEOS stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the NEOS stock intrinsic value calculation we used $9 million for the last fiscal year's total revenue generated by Neos Therapeutics. The default revenue input number comes from 2016 income statement of Neos Therapeutics. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our NEOS stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 8.7%, whose default value for NEOS is calculated based on our internal credit rating of Neos Therapeutics, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Neos Therapeutics.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of NEOS stock the variable cost ratio is equal to 755.6%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for NEOS stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 6.1% for Neos Therapeutics.

Corporate tax rate of 27% is the nominal tax rate for Neos Therapeutics. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the NEOS stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for NEOS are equal to 272.2%.

Life of production assets of 10 years is the average useful life of capital assets used in Neos Therapeutics operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for NEOS is equal to -10%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $-2 million for Neos Therapeutics - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 20.725 million for Neos Therapeutics is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Neos Therapeutics at the current share price and the inputted number of shares is $0.1 billion.

RELATED COMPANIES Price Int.Val. Rating
PFE Pfizer 32.95 28.58  hold
JNJ Johnson&Johnso 133.04 94.54  sell
SUPN Supernus Pharm 43.50 121.76  str.buy
LLY Eli Lilly 77.80 94.86  hold
VRTX Vertex Pharmac 148.54 1,245.01  str.buy
INVA Innoviva 12.51 22.09  str.buy

COMPANY NEWS

▶ Neos Therapeutics reports 2Q loss   [Aug-08-17 08:23PM  Associated Press]
▶ Shire wins U.S. approval for long-acting ADHD drug   [Jun-21-17 04:32AM  Reuters]
▶ Shire's long-acting ADHD drug wins U.S. approval   [Jun-20-17 07:19PM  Reuters]
▶ Two Red Hot Biotechs With Big Near-term Catalysts Ahead   [May-28-17 03:20PM  Motley Fool]
▶ Neos Therapeutics reports 1Q loss   [May-09-17 09:39AM  Associated Press]
▶ Neos Therapeutics reports 4Q loss   [07:08AM  Associated Press]
▶ 5 Stocks with Rising P/E to Enjoy Stellar Gains   [Mar-02-17 08:12AM  Zacks]
Stock chart of NEOS Financial statements of NEOS
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

VALUATION THEORY       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2017. All rigths reserved.